GRI Bio (GRI) Change in Account Payables (2020 - 2026)
GRI Bio (GRI) posted quarterly Change in Account Payables of -$1.5 million for Q1 2026, down 555.29% year-over-year from $331000.0 in Q1 2025, and down 654.04% quarter-over-quarter from $272000.0 in Q4 2025.
GRI Bio (GRI) Change in Account Payables (2020 - 2026) Analysis & Trends
GRI Bio's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 555.29% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$1.2 million (down 270.78% YoY), while the FY2025 annual figure was $663000.0, up 271.32% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1.5 million, down from $272000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.8 million in Q2 2023, with the low at -$2.7 million in Q4 2023.
- The 5-year median for Change in Account Payables is $253000.0 (2024), against an average of $107352.9.
- The sharpest annual moves came in 2023 and 2026: Change in Account Payables surged 34150.0% in 2023, then plunged 555.29% in 2026.
- GRI Bio's Change in Account Payables stood at $820000.0 in 2022, then sank by 429.39% to -$2.7 million in 2023, then jumped by 91.11% to -$240000.0 in 2024, then jumped by 213.33% to $272000.0 in 2025, then plunged by 654.04% to -$1.5 million in 2026.
- Business Quant data shows GRI's Change in Account Payables at -$1.5 million in Q1 2026, $272000.0 in Q4 2025, and $20000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - | 223,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.51 Mn |
| Mar 31, 2026 | -1.51 Mn |
| Dec 31, 2025 | 272,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Dec 31, 2024 | -240,000.00 |
| Dec 31, 2024 | -240,000.00 |
| Sep 30, 2024 | 253,000.00 |
| Sep 30, 2024 | 253,000.00 |
| Jun 30, 2024 | 344,000.00 |
| Jun 30, 2024 | 344,000.00 |
| Mar 31, 2024 | -744,000.00 |
| Mar 31, 2024 | -744,000.00 |
| Dec 31, 2023 | -2.70 Mn |
| Dec 31, 2023 | -2.70 Mn |